Table 2: Chemotherapy details.
|
characteristic |
|
number |
|
|
interval between first and second cycles * |
20-22 days 23-28 days ≥29 days median (range) |
92 10 1 21 (20-32) |
|
|
interval between second and third cycles * |
20-22 days 23-28 days ≥29 days median (range) |
5 3 0 21 (21-28) |
|
|
interval between final cycle and start of radiotherapy * |
18-21days 22-28 days ≥29 days median (range) |
46 46 11 3 24 (18-83) |
|
|
concurrent chemotherapy |
cisplatin + 5FU carboplatin + 5FU cisplatin only cisplatin / carboplatin carboplatin only cetuximab none |
77 1 15 4 2 3 1 |
|
|
overall treatment time †‡ |
two cycles TPF: median (range) three cycles TPF: median (range) |
13.1 (11.1-21.6) 17.7 (15.3-21.3) |
|
|
dose intensity: first cycle |
mean median (range) number with dose reduction § number with ≥90% dose intensity |
99.2 100 (80-100) 8 (7.4%) 104 (96.3%) |
|
|
dose intensity: second cycle |
mean median (range) number with dose reduction number with ≥90% dose intensity |
96.0 100 (67-100) 19 (18.9%) 87 (86.1%) |
|
|
dose intensity: third cycle |
mean median (range) number with dose reduction number with ≥90% dose intensity |
97.1 100 (80-100) 1 (14.3%) 6 (85.7%) |
|
|
mean dose intensity (all TPF cycles) |
mean median (range) number receiving full dose throughout number with ≥90% dose intensity |
97.6 100 (80-100) 85 (80.2%) 94 (88.7%) |
|
|
dose intensity: concurrent chemotherapy |
number with dose reduction week 1 number with dose reduction week 4/5 number with dose reduction week 7 |
4/99 12/99 11/21 |
|
|
mean dose intensity (2-3 cycles concurrent chemotherapy) |
mean median (range) number receiving full dose throughout number with ≥90% mean dose intensity |
97.1 100 (67-100) 87 (85.3%) 91 (89.2%) |
|
*: calculated by subtracting the relevant dates.
†: calculated as the number of days including the first and last (i.e. subtracting the relevant dates plus one).
‡: includes two patients presenting with recurrent disease having surgery between TPF and radiotherapy (61 and 68 days), one patient having radiofrequency ablation for a solitary liver metastasis prior to radiotherapy (55 days) and a further patient referred elsewhere for assessment of resectability prior to radiotherapy (83 days).
§: The first three patients received 5FU infusion over four days rather than five (dose intensity calculated as 93%).